EP0695312A1 - Immunoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation - Google Patents
Immunoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisationInfo
- Publication number
- EP0695312A1 EP0695312A1 EP94914433A EP94914433A EP0695312A1 EP 0695312 A1 EP0695312 A1 EP 0695312A1 EP 94914433 A EP94914433 A EP 94914433A EP 94914433 A EP94914433 A EP 94914433A EP 0695312 A1 EP0695312 A1 EP 0695312A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunonanoparticles
- anticoφs
- nanoparticles
- monoclonal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002105 nanoparticle Substances 0.000 claims abstract description 35
- 229920000642 polymer Polymers 0.000 claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 9
- -1 methyliden malonate compound Chemical class 0.000 claims abstract description 9
- 230000007170 pathology Effects 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 4
- 108010041397 CD4 Antigens Proteins 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229940088623 biologically active substance Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000376 reactant Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical compound O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- HFQQYIUTYJVYFZ-UHFFFAOYSA-N 4-methylpentyl 2-cyanoprop-2-enoate Chemical compound CC(C)CCCOC(=O)C(=C)C#N HFQQYIUTYJVYFZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical compound CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US101700 | 1987-09-28 | ||
FR9304750A FR2704227B1 (fr) | 1993-04-22 | 1993-04-22 | Immunonanoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues a une infection par le virus hiv. |
FR9304750 | 1993-04-22 | ||
US10170093A | 1993-08-04 | 1993-08-04 | |
PCT/FR1994/000459 WO1994024168A1 (fr) | 1993-04-22 | 1994-04-22 | Immunoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0695312A1 true EP0695312A1 (fr) | 1996-02-07 |
Family
ID=26230266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94914433A Ceased EP0695312A1 (fr) | 1993-04-22 | 1994-04-22 | Immunoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0695312A1 (fr) |
JP (1) | JPH08512287A (fr) |
CN (1) | CN1121725A (fr) |
AU (1) | AU6681494A (fr) |
CA (1) | CA2160983A1 (fr) |
CZ (1) | CZ276295A3 (fr) |
FI (1) | FI954827A (fr) |
HU (1) | HUT73392A (fr) |
SK (1) | SK130395A3 (fr) |
WO (1) | WO1994024168A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722411B1 (fr) * | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv |
JP4611561B2 (ja) * | 2000-04-12 | 2011-01-12 | Dic株式会社 | 新規なビニル系樹脂およびその製造方法 |
GB2381792B (en) * | 2000-04-12 | 2004-08-04 | Dainippon Ink & Chemicals | Antifouling coating composituion |
JP3961312B2 (ja) | 2002-02-26 | 2007-08-22 | 株式会社デンソー | 内燃機関の制御装置 |
WO2012113348A1 (fr) * | 2011-02-25 | 2012-08-30 | 厦门大学 | Anticorps monoclonal anti-protéine cd4, fragments actifs et utilisations de celui-ci |
CN110903394B (zh) * | 2019-12-27 | 2021-09-07 | 源道隆(苏州)医学科技有限公司 | 可结合cd4的多肽及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0329184A3 (fr) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimères et conjugaison antimère |
-
1994
- 1994-04-22 CN CN94191869A patent/CN1121725A/zh active Pending
- 1994-04-22 CZ CZ952762A patent/CZ276295A3/cs unknown
- 1994-04-22 JP JP6522857A patent/JPH08512287A/ja active Pending
- 1994-04-22 WO PCT/FR1994/000459 patent/WO1994024168A1/fr not_active Application Discontinuation
- 1994-04-22 CA CA002160983A patent/CA2160983A1/fr not_active Abandoned
- 1994-04-22 HU HU9503028A patent/HUT73392A/hu unknown
- 1994-04-22 EP EP94914433A patent/EP0695312A1/fr not_active Ceased
- 1994-04-22 AU AU66814/94A patent/AU6681494A/en not_active Abandoned
- 1994-04-22 SK SK1303-95A patent/SK130395A3/sk unknown
-
1995
- 1995-10-11 FI FI954827A patent/FI954827A/fi unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9424168A1 * |
Also Published As
Publication number | Publication date |
---|---|
SK130395A3 (en) | 1996-06-05 |
CN1121725A (zh) | 1996-05-01 |
JPH08512287A (ja) | 1996-12-24 |
FI954827A0 (fi) | 1995-10-11 |
HU9503028D0 (en) | 1995-12-28 |
WO1994024168A1 (fr) | 1994-10-27 |
CA2160983A1 (fr) | 1994-10-27 |
FI954827A (fi) | 1995-10-11 |
AU6681494A (en) | 1994-11-08 |
HUT73392A (en) | 1996-07-29 |
CZ276295A3 (en) | 1996-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Knight et al. | Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. | |
FR2615394A1 (fr) | Utilisation de certains 17-cetosteroides, eventuellement avec un immunomodulateur et/ou un agent antiviral, pour fabriquer un medicament pour le traitement et la prevention des infections retrovirales | |
JPH10513053A (ja) | 未分化細胞の製造方法 | |
EP0240424B1 (fr) | Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament | |
FR2516794A1 (fr) | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique | |
JP4216076B2 (ja) | 性的に伝達される病気の予防および治療のための薬剤−i | |
WO1994024168A1 (fr) | Immunoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation | |
CA2473490A1 (fr) | Corps porteurs de peptides pour reponse immunitaire | |
EP1851321B1 (fr) | Epitopes de vih et composition pharmaceutique les contenant | |
AU783250B2 (en) | Autologous adoptive immunotherapy with primed antigen-specific T cells or B cells | |
WO1993009791A2 (fr) | Utilisation de derives d'amphotericine b, comme inhibiteurs de proteases | |
Esparza et al. | Inhibition of macrophage tumoricidal activity by immune complexes and altered erythrocytes. | |
FR2704227A1 (fr) | Immunonanoparticules porteuses d'anticorps monoclonaux anti-CD4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues à une infection par le virus HIV. | |
WO1996002278A1 (fr) | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta-2 microglobuline | |
Dore-Duffy | Differential effect of prostaglandins and other products of arachidonic acid metabolism on measles virus replication in Vero cells | |
FR2626472A1 (fr) | Utilisation des proteines du lait pour la fabrication d'un medicament antiviral | |
JP2022537967A (ja) | 同種異系car-t細胞療法 | |
JPH08501803A (ja) | アミノ糖および糖蛋白、その製法、それらアミノ糖または糖蛋白を含む医薬製剤およびそれらの製剤の用途 | |
EP1663146B1 (fr) | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation | |
US5669396A (en) | Methods of detecting and treating vaso-occlusive crisis in sickle cell disease | |
WO2002079298A1 (fr) | Agents pour la prevention et le traitement de maladies sexuellement transmissibles - ii | |
EP0804408B1 (fr) | Nouveaux composes 2,6-di-tert-butylphenols substitues en position 4, les compositions pharmaceutiques les contenant et leur procede de preparation | |
EP0149581A2 (fr) | Nouvelles compositions contenant des oligo-muramylpeptides et leur application, notamment pour l'activation des macrophages | |
Breton et al. | Biocompatible poly (methylidene malonate)-made materials for pharmaceutical and biomedical applications | |
AU735990B2 (en) | Amino sugars and glycoproteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951017 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 951017 |
|
RAX | Requested extension states of the european patent have changed |
Free format text: SI PAYMENT 951017 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BRETON, PASCAL Inventor name: TEULON, JEAN-MARIE Inventor name: LESCURE, FRANCOIS Inventor name: CHERMANN, JEAN-CLAUDE, 8,ROUTE DE LA TREILLE Inventor name: BRU-MAGNIERZ, NICOLE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19960415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19961204 |